Investigating how UBR5 affects B cell development and activation
Role of E3 Ligase UBR5 in Alternative Splicing during B Cell Development and Activation
['FUNDING_R01'] · UNIVERSITY OF UTAH · NIH-10888376
This study is looking at how a protein called UBR5 affects the growth and function of B cells, which are important for our immune system, especially in certain cancers like mantle cell lymphoma, to help us understand how changes in this protein might influence immune health.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF UTAH (nih funded) |
| Locations | 1 site (SALT LAKE CITY, UNITED STATES) |
| Trial ID | NIH-10888376 on ClinicalTrials.gov |
What this research studies
This research focuses on understanding the role of the UBR5 protein in the development and activation of B cells, which are crucial for the immune response. The study examines how mutations in UBR5 can impact B cell maturation and function, particularly in the context of certain cancers like mantle cell lymphoma. By using a conditional mutant model, researchers will explore the molecular mechanisms by which UBR5 influences B cell behavior, including its interaction with splicing factors and the spliceosome. The findings could provide insights into the fundamental processes of B cell biology and their implications for immune health.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with B cell malignancies, particularly those with mantle cell lymphoma or related conditions.
Not a fit: Patients with non-B cell related cancers or those without any B cell disorders may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies for treating B cell-related disorders, including certain types of cancer.
How similar studies have performed: Previous research has shown that targeting molecular mechanisms in B cell development can lead to significant advancements in understanding and treating B cell malignancies.
Where this research is happening
SALT LAKE CITY, UNITED STATES
- UNIVERSITY OF UTAH — SALT LAKE CITY, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: BUCKLEY, SHANNON — UNIVERSITY OF UTAH
- Study coordinator: BUCKLEY, SHANNON
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.